ロード中...

Learning from the Recently Completed Oral Glycoprotein IIb/IIIa Receptor Antagonist Trials

Although parenteral therapy with glycoprotein (GP) IIb/IIIa inhibitors has resulted in a reduced risk of death or myocardial infarction in patients with acute coronary syndromes and in patients undergoing percutaneous coronary intervention, the benefit is achieved only during the infusion period. Or...

詳細記述

保存先:
書誌詳細
出版年:Clin Cardiol
第一著者: Cannon, Christopher P.
フォーマット: Artigo
言語:Inglês
出版事項: Wiley Periodicals, Inc. 2009
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6654967/
https://ncbi.nlm.nih.gov/pubmed/11129681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.4960231105
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!